A comparative, cross-over, double blind, randomized study for bioequivalence assessment between two formulations of valsartan capsules vs. tablets;Estudio comparativo, cruzado, doble ciego, al azar para determinar la bioequivalencia entre dos formulaciones de valsartán en tabletas y cápsulas

Colombia Medica

Volumn 37, Issue 2, 2006, Pages 107-113

  Pérez, Milena ^a   Cárdenas, William ^a   Ramírez, Gloria ^a   Pérez, Mauricio ^a   Restrepo, Piedad ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

Bioavailability; Bioequivalence; Valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; LOSARTAN; PLACEBO; VALSARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMAN; HUMAN EXPERIMENT; MALE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 33745588527     PISSN: 16579534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Center for Drug Evaluation and Research Department of Health and Human Services. Approval Package for Application Number 21-283/S 002. Printed Labeling. Novartis Pharmaceutical Co. Prescribing Information. Approved 2002.
2. World Health Organization. Manual on marketing authorization of pharmaceutical products. Geneva: WHO; 1998.
3. World Health Organization. Quality assurance of pharmaceuticals. Geneva: WHO; 1997.
4. World Health Organization. Marketing authorization of pharmaceutical products with special reference to multisource (generics) products: a manual for drug regulatory authorities. Geneva: WHO; 1998.
5. González JA, L-acopez RM, Alonso, RM. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high performance liquid chromatography with fluorimetric detection. J Chromatogr 2002; 949: 49-60.
6. Tatar S, Saglik S. Comparison of UV- and second derivate-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. J Pharm Biomed Anal 2002; 30: 371-375.
7. Ministerio de Salud. Agencia Nacional de Vigilancia Sanitaria. Manual de buenas prácticas de biodisponibilidad y bioequivalencia. Brasilia: Ministerio de Salud; 2002.
8. Huber L. Validation of analytical methods: Review and strategy LC/GC international. Labcompliance 1998; Feb: 96-105.
9. Food and Drug Administration. Guidance for industry: Analytical procedures and methods validation. US: Food and Drug Administration; 2000.
10. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation. A revisit with a decade of progress. Pharm Res 2000; 17: 1551-1557.
11. Food and Drug Administration. International Conference on Harmonization. Guideline on the validation of analytical procedures. Methodology, availability. US: Food and Drug Administration; 1997.